HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) represents an unmet clinical need due to the very poor prognosis and the lack of effective therapy. Here we investigated the potential of domatinostat (4SC-202), a new class I histone deacetylase (HDAC) inhibitor, currently in clinical development,...

Descripción completa

Detalles Bibliográficos
Autores principales: Roca, Maria Serena, Moccia, Tania, Iannelli, Federica, Testa, Cristina, Vitagliano, Carlo, Minopoli, Michele, Camerlingo, Rosa, De Riso, Giulia, De Cecio, Rossella, Bruzzese, Francesca, Conte, Mariarosaria, Altucci, Lucia, Di Gennaro, Elena, Avallone, Antonio, Leone, Alessandra, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892808/
https://www.ncbi.nlm.nih.gov/pubmed/35241126
http://dx.doi.org/10.1186/s13046-022-02295-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892808/
https://www.ncbi.nlm.nih.gov/pubmed/35241126
http://dx.doi.org/10.1186/s13046-022-02295-4

Ejemplares similares